A global Phase I clinical trial involved 38 patients with FGFR4-driven HCC who had undergone multiple chemotherapy treatments; six patients (16%) achieved objective responses, 26 patients (68%) had disease control, and 18 patients (49%) experienced a reduction in tumor burden. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.